Eric Karas - Jan 2, 2025 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
Chief Commercial Officer
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
Jan 2, 2025
Transactions value $
$0
Form type
4
Date filed
1/3/2025, 04:30 PM
Previous filing
Dec 4, 2024
Next filing
Mar 21, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock option (right to buy) Award $0 +152K $0.00 152K Jan 2, 2025 Common Stock 152K $10.71 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025.